Adoptive Cell Therapy in Hepatocellular Carcinoma: Biological Rationale and First Results in Early Phase Clinical Trials - Archive ouverte HAL Access content directly
Journal Articles Cancers Year : 2021

Adoptive Cell Therapy in Hepatocellular Carcinoma: Biological Rationale and First Results in Early Phase Clinical Trials

(1, 2) , (1) , (3, 4) , (5) , (1) , (1)
1
2
3
4
5

Abstract

The mortality of hepatocellular carcinoma (HCC) is quickly increasing worldwide. In unresectable HCC, the cornerstone of systemic treatments is switching from tyrosine kinase inhibitors to immune checkpoints inhibitors (ICI). Next to ICI, adoptive cell transfer represents another promising field of immunotherapy. Targeting tumor associated antigens such as alpha-fetoprotein (AFP), glypican-3 (GPC3), or New York esophageal squamous cell carcinoma-1 (NY-ESO-1), T cell receptor (TCR) engineered T cells and chimeric antigen receptors (CAR) engineered T cells are emerging as potentially effective therapies, with objective responses reported in early phase trials. In this review, we address the biological rationale of TCR/CAR engineered T cells in advanced HCC, their mechanisms of action, and results from recent clinical trials.

Dates and versions

hal-03689931 , version 1 (07-06-2022)

Identifiers

Cite

Philippe Rochigneux, Brice Chanez, Bernadette de Rauglaudre, Emmanuel Mitry, Christian Chabannon, et al.. Adoptive Cell Therapy in Hepatocellular Carcinoma: Biological Rationale and First Results in Early Phase Clinical Trials. Cancers, 2021, 13 (2), pp.271. ⟨10.3390/cancers13020271⟩. ⟨hal-03689931⟩
7 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More